Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Padcev-Keytruda Combo Lands Another Win in Bladder Cancer

Summary by MedPage Today
(MedPage Today) -- SAN FRANCISCO -- Perioperative treatment with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) significantly improved survival compared with standard neoadjuvant chemotherapy in patients with muscle-invasive bladder...

2 Articles

MedPage TodayMedPage Today
Center

Padcev-Keytruda Combo Lands Another Win in Bladder Cancer

(MedPage Today) -- SAN FRANCISCO -- Perioperative treatment with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) significantly improved survival compared with standard neoadjuvant chemotherapy in patients with muscle-invasive bladder...

·New York, United States
Read Full Article
cancernetwork.comcancernetwork.com

Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial

Phase 3 data support perioperative enfortumab vedotin plus pembrolizumab as a novel treatment option in MIBC regardless of eligibility for cisplatin.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States on Friday, February 27, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Francisco, California icon

San Francisco, California

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal